The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Dementia Associated with Alzimer’s Disease Market Research Report 2025
Synopsis
The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and others. The cholinergic/ cholinesterase (ChE) inhibitor segment dominates the dementia associated with Alzheimer’s disease market,
The global Dementia Associated with Alzimer’s Disease market was valued at US$ 4212.1 million in 2023 and is anticipated to reach US$ 5034.7 million by 2030, witnessing a CAGR of 2.6% during the forecast period 2024-2030.
North American market for Dementia Associated with Alzimer’s Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Dementia Associated with Alzimer’s Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Dementia Associated with Alzimer’s Disease in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Dementia Associated with Alzimer’s Disease include Merz Pharma, Novartis, Allergan, Pfizer, Daiichi Sankyo Company, Ono Pharmaceutical, Johnson & Johnson, Eisai and H. Lundbeck, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Dementia Associated with Alzimer’s Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dementia Associated with Alzimer’s Disease.
Report Scope
The Dementia Associated with Alzimer’s Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dementia Associated with Alzimer’s Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dementia Associated with Alzimer’s Disease companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merz Pharma
Novartis
Allergan
Pfizer
Daiichi Sankyo Company
Ono Pharmaceutical
Johnson & Johnson
Eisai
H. Lundbeck
F. Hoffmann-La Roche
Segment by Type
Cholinergic/ Cholinesterase (ChE) Inhibitors
Memantine
Combined Drug (Memantine & Donepezil)
Others
Segment by Application
Hospital Pharmacies
Retail
Online Sales
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dementia Associated with Alzimer’s Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global dementia associated with Alzheimer’s disease market has been segmented based on drug class and distribution channel. In terms of drug class, the global market has been classified into cholinergic/ cholinesterase (ChE) inhibitor, memantine, and combined drug (memantine & donepezil) and others. The cholinergic/ cholinesterase (ChE) inhibitor segment dominates the dementia associated with Alzheimer’s disease market,
The global Dementia Associated with Alzimer’s Disease market was valued at US$ 4212.1 million in 2023 and is anticipated to reach US$ 5034.7 million by 2030, witnessing a CAGR of 2.6% during the forecast period 2024-2030.
North American market for Dementia Associated with Alzimer’s Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Dementia Associated with Alzimer’s Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Dementia Associated with Alzimer’s Disease in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Dementia Associated with Alzimer’s Disease include Merz Pharma, Novartis, Allergan, Pfizer, Daiichi Sankyo Company, Ono Pharmaceutical, Johnson & Johnson, Eisai and H. Lundbeck, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Dementia Associated with Alzimer’s Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dementia Associated with Alzimer’s Disease.
Report Scope
The Dementia Associated with Alzimer’s Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dementia Associated with Alzimer’s Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dementia Associated with Alzimer’s Disease companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merz Pharma
Novartis
Allergan
Pfizer
Daiichi Sankyo Company
Ono Pharmaceutical
Johnson & Johnson
Eisai
H. Lundbeck
F. Hoffmann-La Roche
Segment by Type
Cholinergic/ Cholinesterase (ChE) Inhibitors
Memantine
Combined Drug (Memantine & Donepezil)
Others
Segment by Application
Hospital Pharmacies
Retail
Online Sales
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dementia Associated with Alzimer’s Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dementia Associated with Alzimer’s Disease Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cholinergic/ Cholinesterase (ChE) Inhibitors
1.2.3 Memantine
1.2.4 Combined Drug (Memantine & Donepezil)
1.2.5 Others
1.3 Market by Application
1.3.1 Global Dementia Associated with Alzimer’s Disease Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail
1.3.4 Online Sales
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Dementia Associated with Alzimer’s Disease Market Perspective (2019-2030)
2.2 Dementia Associated with Alzimer’s Disease Growth Trends by Region
2.2.1 Global Dementia Associated with Alzimer’s Disease Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Dementia Associated with Alzimer’s Disease Historic Market Size by Region (2019-2024)
2.2.3 Dementia Associated with Alzimer’s Disease Forecasted Market Size by Region (2025-2030)
2.3 Dementia Associated with Alzimer’s Disease Market Dynamics
2.3.1 Dementia Associated with Alzimer’s Disease Industry Trends
2.3.2 Dementia Associated with Alzimer’s Disease Market Drivers
2.3.3 Dementia Associated with Alzimer’s Disease Market Challenges
2.3.4 Dementia Associated with Alzimer’s Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dementia Associated with Alzimer’s Disease Players by Revenue
3.1.1 Global Top Dementia Associated with Alzimer’s Disease Players by Revenue (2019-2024)
3.1.2 Global Dementia Associated with Alzimer’s Disease Revenue Market Share by Players (2019-2024)
3.2 Global Dementia Associated with Alzimer’s Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dementia Associated with Alzimer’s Disease Revenue
3.4 Global Dementia Associated with Alzimer’s Disease Market Concentration Ratio
3.4.1 Global Dementia Associated with Alzimer’s Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dementia Associated with Alzimer’s Disease Revenue in 2023
3.5 Dementia Associated with Alzimer’s Disease Key Players Head office and Area Served
3.6 Key Players Dementia Associated with Alzimer’s Disease Product Solution and Service
3.7 Date of Enter into Dementia Associated with Alzimer’s Disease Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Dementia Associated with Alzimer’s Disease Breakdown Data by Type
4.1 Global Dementia Associated with Alzimer’s Disease Historic Market Size by Type (2019-2024)
4.2 Global Dementia Associated with Alzimer’s Disease Forecasted Market Size by Type (2025-2030)
5 Dementia Associated with Alzimer’s Disease Breakdown Data by Application
5.1 Global Dementia Associated with Alzimer’s Disease Historic Market Size by Application (2019-2024)
5.2 Global Dementia Associated with Alzimer’s Disease Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Dementia Associated with Alzimer’s Disease Market Size (2019-2030)
6.2 North America Dementia Associated with Alzimer’s Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Dementia Associated with Alzimer’s Disease Market Size by Country (2019-2024)
6.4 North America Dementia Associated with Alzimer’s Disease Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Dementia Associated with Alzimer’s Disease Market Size (2019-2030)
7.2 Europe Dementia Associated with Alzimer’s Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Dementia Associated with Alzimer’s Disease Market Size by Country (2019-2024)
7.4 Europe Dementia Associated with Alzimer’s Disease Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dementia Associated with Alzimer’s Disease Market Size (2019-2030)
8.2 Asia-Pacific Dementia Associated with Alzimer’s Disease Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Dementia Associated with Alzimer’s Disease Market Size by Region (2019-2024)
8.4 Asia-Pacific Dementia Associated with Alzimer’s Disease Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Dementia Associated with Alzimer’s Disease Market Size (2019-2030)
9.2 Latin America Dementia Associated with Alzimer’s Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Dementia Associated with Alzimer’s Disease Market Size by Country (2019-2024)
9.4 Latin America Dementia Associated with Alzimer’s Disease Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dementia Associated with Alzimer’s Disease Market Size (2019-2030)
10.2 Middle East & Africa Dementia Associated with Alzimer’s Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Dementia Associated with Alzimer’s Disease Market Size by Country (2019-2024)
10.4 Middle East & Africa Dementia Associated with Alzimer’s Disease Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merz Pharma
11.1.1 Merz Pharma Company Detail
11.1.2 Merz Pharma Business Overview
11.1.3 Merz Pharma Dementia Associated with Alzimer’s Disease Introduction
11.1.4 Merz Pharma Revenue in Dementia Associated with Alzimer’s Disease Business (2019-2024)
11.1.5 Merz Pharma Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Dementia Associated with Alzimer’s Disease Introduction
11.2.4 Novartis Revenue in Dementia Associated with Alzimer’s Disease Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Allergan
11.3.1 Allergan Company Detail
11.3.2 Allergan Business Overview
11.3.3 Allergan Dementia Associated with Alzimer’s Disease Introduction
11.3.4 Allergan Revenue in Dementia Associated with Alzimer’s Disease Business (2019-2024)
11.3.5 Allergan Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Dementia Associated with Alzimer’s Disease Introduction
11.4.4 Pfizer Revenue in Dementia Associated with Alzimer’s Disease Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Daiichi Sankyo Company
11.5.1 Daiichi Sankyo Company Company Detail
11.5.2 Daiichi Sankyo Company Business Overview
11.5.3 Daiichi Sankyo Company Dementia Associated with Alzimer’s Disease Introduction
11.5.4 Daiichi Sankyo Company Revenue in Dementia Associated with Alzimer’s Disease Business (2019-2024)
11.5.5 Daiichi Sankyo Company Recent Development
11.6 Ono Pharmaceutical
11.6.1 Ono Pharmaceutical Company Detail
11.6.2 Ono Pharmaceutical Business Overview
11.6.3 Ono Pharmaceutical Dementia Associated with Alzimer’s Disease Introduction
11.6.4 Ono Pharmaceutical Revenue in Dementia Associated with Alzimer’s Disease Business (2019-2024)
11.6.5 Ono Pharmaceutical Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Dementia Associated with Alzimer’s Disease Introduction
11.7.4 Johnson & Johnson Revenue in Dementia Associated with Alzimer’s Disease Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 Eisai
11.8.1 Eisai Company Detail
11.8.2 Eisai Business Overview
11.8.3 Eisai Dementia Associated with Alzimer’s Disease Introduction
11.8.4 Eisai Revenue in Dementia Associated with Alzimer’s Disease Business (2019-2024)
11.8.5 Eisai Recent Development
11.9 H. Lundbeck
11.9.1 H. Lundbeck Company Detail
11.9.2 H. Lundbeck Business Overview
11.9.3 H. Lundbeck Dementia Associated with Alzimer’s Disease Introduction
11.9.4 H. Lundbeck Revenue in Dementia Associated with Alzimer’s Disease Business (2019-2024)
11.9.5 H. Lundbeck Recent Development
11.10 F. Hoffmann-La Roche
11.10.1 F. Hoffmann-La Roche Company Detail
11.10.2 F. Hoffmann-La Roche Business Overview
11.10.3 F. Hoffmann-La Roche Dementia Associated with Alzimer’s Disease Introduction
11.10.4 F. Hoffmann-La Roche Revenue in Dementia Associated with Alzimer’s Disease Business (2019-2024)
11.10.5 F. Hoffmann-La Roche Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
